Supporting Information

Effect of Renal Impairment on the pharmacokinetics and pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

Authors
Sachiya Ikeda, Yasuki Takano, Dietmar Schwab, Agnes Portron, Nahoko Kasahara-Ito, Tomohisa Saito, Satofumi Iida

Affiliations
1Primary lifecycle management Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
2Clinical Science and Strategy Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
3Pharmaceutical Sciences, Clinical Pharmacology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
4Translational Clinical Research, Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

Correspondence
Sachiya Ikeda
Primary Lifecycle Management Department
Chugai Pharmaceutical Co., Ltd.
2-1-1 Nihonbashi Muromachi,
Chuo-ku
Tokyo 103-8324
Japan
Tel.: +81/3/3273 4368
Fax: +81/3/3281 0191
E-mail: ikedascy@chugai-pharm.co.jp
Scatterplot: eGFR vs CL/F

\[ \text{CL}_F = 9.24 + 0.017 \text{ GFR} + e \]

\[ R^2 = 0.02 \]

\[ \hat{\mu} = 10.348 \]

Datetime: June 14, 2018 15:16:00